By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Celltrion Healthcare (Formerly Known As Celltrion) 

1000 Marina Boulevard
Suite 200
Brisbane  California  94005  U.S.A.
Phone: N/A Fax:


SEARCH JOBS

Celltrion Healthcare conducts the worldwide marketing, sales and distribution of biological medicines developed by Celltrion, Inc. through an extensive global network that spans more than 120 different countries. Celltrion Healthcare’s products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US Food and Drug Administration (FDA) cGMP guidelines and the EU GMP guidelines.

YEAR FOUNDED:

1999

LEADERSHIP:

CEO: Jung Jini

CLINICAL TRIAL:

Please click here for clinical trial information.

PRODUCTS:

All Products

FOLLOW CELLTRION:




Key Statistics


Email: sshong@celltrion.com
Ownership: Public

Web Site: Celltrion Healthcare
Employees:
Symbol: 068270.KQ
 



Industry
Biotechnology






Company News
Celltrion Healthcare (068270.KQ) Showcases Data Supporting Efficacy And Safety Of Both CT-P10 And CT-P13 Biosimilars 11/14/2016 11:54:41 AM
Week In Review: Teva (TEVA) Pays $160 Million For US/Canada Rights To Celltrion (068270.KQ) Biosimilars 10/10/2016 9:19:29 AM
Teva (TEVA) Pays $160 Million to Celltrion (068270.KQ) in Biosimilar Hook-Up 10/6/2016 7:03:59 AM
Celltrion (068270.KQ) Announces Its Commitment To Develop Anti-Drug Antibody And Drug Concentration Assay To Enable Evidence-Based Decision-Making In anti-TNF Treatment 7/5/2016 11:23:45 AM
FDAAdvisoryCommittee.com Approves Celltrion (068270.KQ)’s INFLECTRA, the First Cheaper Version of Johnson & Johnson (JNJ) Blockbuster Remicade 4/6/2016 6:19:31 AM
FDA’s Arthritis Advisory Committee Recommends Approval Of Celltrion (068270.KQ)’s CT-P13, A Proposed Biosimilar Infliximab, For All Indications 2/10/2016 11:05:25 AM
Johnson & Johnson (JNJ) Falls as FDA Staffers Back Celltrion (068270.KQ)'s Remicade Biosimilar 2/8/2016 6:15:00 AM
Celltrion, Inc. (068270.KQ) And Medidata Team Up To Transform Global Clinical Trials For Biosimilars 1/21/2016 10:39:15 AM
Celltrion, Inc. (068270.KQ): No Difference In Efficacy Or Immunogenicity Following Switch To Remsima®? (Infliximab) From Originator 10/28/2015 10:59:37 AM
Celltrion, Inc. (068270.KQ) Launches World’s First Biosimilar Monoclonal Antibody Remsima In 12 New European Markets 2/25/2015 12:03:28 PM
1234
//-->